Header Logo

Matthew Meriggioli

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentNeurological Sciences
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 6603932829.
    My NIH COMMONS name is MERIGGIOLIM.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. GomezMancilla B, Meriggioli MN, Genge A, Roubenoff R, Espi? P, Dupuy C, Hartmann N, Pezous N, Kinhikar A, Tichy M, Dionne A, Vissing J, Andersen H, Schoser B, Meisel A, Jordan B, Devlikamova F, Poverennova I, Stuchevskaya F, Lin TS, Rush JS, Gergely P. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. J Clin Neurosci. 2024 Jan; 119:76-84. PMID: 37988976.
      Citations:    
    2. Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, Reash NF, Iammarino MA, Church KR, Kleyn A, Meriggioli MN, Shell R. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021 07 01; 78(7):834-841. PMID: 33999158.
      Citations:    
    3. Cooper DS, Meriggioli MN, Bonomi PD, Malik R. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173. PMID: 28505981.
      Citations:    
    4. Meriggioli MN. The Clinical Spectrum of Necrotizing Autoimmune Myopathy: A Mixed Bag With Blurred Lines. JAMA Neurol. 2015 Sep; 72(9):977-9. PMID: 26192089.
      Citations:    
    5. Meriggioli MN, Roubenoff R. Prospect for pharmacological therapies to treat skeletal muscle dysfunction. Calcif Tissue Int. 2015 Mar; 96(3):234-42. PMID: 25363509.
      Citations:    
    6. Thiruppathi M, Rowin J, Ganesh B, Sheng JR, Prabhakar BS, Meriggioli MN. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol. 2012 Dec; 145(3):209-23. PMID: 23110942.
      Citations:    
    7. Rowin J, Thiruppathi M, Arhebamen E, Sheng J, Prabhakar BS, Meriggioli MN. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012 Sep; 46(3):449-53. PMID: 22907239.
      Citations:    
    8. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012 Jul; 8(5):427-38. PMID: 22882218.
      Citations:    
    9. Brown CA, Scharner J, Felice K, Meriggioli MN, Tarnopolsky M, Bower M, Zammit PS, Mendell JR, Ellis JA. Novel and recurrent EMD mutations in patients with Emery-Dreifuss muscular dystrophy, identify exon 2 as a mutation hot spot. J Hum Genet. 2011 Aug; 56(8):589-94. PMID: 21697856.
      Citations:    
    10. Scharner J, Brown CA, Bower M, Iannaccone ST, Khatri IA, Escolar D, Gordon E, Felice K, Crowe CA, Grosmann C, Meriggioli MN, Asamoah A, Gordon O, Gnocchi VF, Ellis JA, Mendell JR, Zammit PS. Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Hum Mutat. 2011 Feb; 32(2):152-67. PMID: 20848652.
      Citations:    
    11. Sheng JR, Li LC, Prabhakar BS, Meriggioli MN. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve. 2009 Aug; 40(2):279-86. PMID: 19609914.
      Citations:    
    12. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009 May; 8(5):475-90. PMID: 19375665.
      Citations:    
    13. Meriggioli MN, Sheng JR, Li L, Prabhakar BS. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci. 2008; 1132:276-82. PMID: 18567878.
      Citations:    
    14. Meriggioli MN. IVIG in myasthenia gravis: getting enough "bang for the buck". Neurology. 2007 Mar 13; 68(11):803-4. PMID: 17353466.
      Citations:    
    15. Rowin J, Cheng G, Lewis SL, Meriggioli MN. Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve. 2006 Nov; 34(5):666-9. PMID: 16897763.
      Citations:    
    16. Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil. 2005 Aug; 84(8):627-38. PMID: 16034233.
      Citations:    
    17. Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol. 2004 Mar; 24(1):31-9. PMID: 15229790.
      Citations:    
    18. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25; 61(10):1438-40. PMID: 14638974.
      Citations:    
    19. Gordon AJ, Meriggioli MN. Clinical immunopharmacology of autoimmune neuropathies and myopathies. Clin Neuropharmacol. 2002 May-Jun; 25(3):174-81. PMID: 12023571.
      Citations:    
    20. Rowin J, Meriggioli MN. Complex repetitive discharges: cause or effect of neurogenic muscle hypertrophy? Muscle Nerve. 1999 Nov; 22(11):1603-6. PMID: 10514243.
      Citations:    
    21. Camici M, Giordani R, Morelli E, Meriggioli M, Balestri PL, Barsotti G, Sagripanti A. Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin. Minerva Med. 1998 Nov-Dec; 89(11-12):405-9. PMID: 10212664.
      Citations:    
    22. Barsotti G, Cupisti A, Ferdeghini M, Meola M, Battini S, Cozza V, Meriggioli M, Barsotti M. Circulating levels of IGF-I in patients with chronic uremia on conservative dietary treatment. Ren Fail. 1998 Mar; 20(2):357-60. PMID: 9574463.
      Citations:    
    23. Meriggioli MN, Morgenlander JC. Peripheral neuropathy and connective tissue disease. Watch for this twosome when hunting for a diagnosis. Postgrad Med. 1997 Nov; 102(5):65-8, 71, 75. PMID: 9385332.
      Citations:    
    24. Camici M, Evangelisti L, Balestri P, Cioni L, Rindi P, Sagripanti A, Meriggioli M, Giordani R. Coagulation activation in extracorporeal hemodialysis. Int J Artif Organs. 1997 Mar; 20(3):163-5. PMID: 9151152.
      Citations:    
    25. Camici M, Evangelisti L, Balestri P, Cioni L, Rindi P, Sagripanti A, Meriggioli M, Giordani R. [Coagulation in hemodialysis]. Minerva Med. 1996 Nov; 87(11):509-14. PMID: 9045101.
      Citations:    
    Meriggioli's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (162)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _